Creative Planning lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 38.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,593 shares of the life sciences company’s stock after acquiring an additional 4,083 shares during the period. Creative Planning’s holdings in Illumina were worth $4,439,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in ILMN. Broderick Brian C raised its stake in Illumina by 0.3% in the 2nd quarter. Broderick Brian C now owns 13,240 shares of the life sciences company’s stock valued at $4,874,000 after purchasing an additional 36 shares during the last quarter. Foresight Wealth Management LLC grew its holdings in Illumina by 4.2% in the 2nd quarter. Foresight Wealth Management LLC now owns 972 shares of the life sciences company’s stock valued at $358,000 after buying an additional 39 shares during the period. Bbva USA Bancshares Inc. grew its holdings in Illumina by 2.0% in the 2nd quarter. Bbva USA Bancshares Inc. now owns 2,020 shares of the life sciences company’s stock valued at $743,000 after buying an additional 40 shares during the period. Zeke Capital Advisors LLC grew its holdings in Illumina by 2.0% in the 3rd quarter. Zeke Capital Advisors LLC now owns 2,044 shares of the life sciences company’s stock valued at $622,000 after buying an additional 40 shares during the period. Finally, Greenleaf Trust grew its holdings in Illumina by 0.6% in the 2nd quarter. Greenleaf Trust now owns 6,691 shares of the life sciences company’s stock valued at $2,463,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 90.94% of the company’s stock.
Several analysts have commented on ILMN shares. Piper Jaffray Companies lowered their price target on Illumina from $348.00 to $341.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Deutsche Bank lowered their price target on Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a report on Friday, July 12th. Credit Suisse Group restated a “buy” rating and issued a $340.00 price target on shares of Illumina in a report on Wednesday, July 31st. Cowen set a $320.00 target price on Illumina and gave the stock a “buy” rating in a report on Friday, October 25th. Finally, Guggenheim started coverage on Illumina in a report on Friday, October 25th. They set a “buy” rating and a $350.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. Illumina presently has a consensus rating of “Buy” and a consensus price target of $333.38.
In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $285.52, for a total value of $2,855,200.00. Following the completion of the transaction, the senior vice president now owns 86,585 shares in the company, valued at approximately $24,721,749.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 193 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $297.28, for a total value of $57,375.04. Following the completion of the transaction, the senior vice president now owns 5,069 shares of the company’s stock, valued at approximately $1,506,912.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,638 shares of company stock valued at $9,580,415. 0.38% of the stock is owned by company insiders.
Shares of NASDAQ:ILMN traded down $2.34 during trading on Friday, reaching $292.91. 22,453 shares of the stock were exchanged, compared to its average volume of 1,057,488. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.15 and a current ratio of 6.82. Illumina, Inc. has a 12-month low of $263.30 and a 12-month high of $380.76. The firm has a market cap of $44.23 billion, a price-to-earnings ratio of 51.21, a price-to-earnings-growth ratio of 2.22 and a beta of 1.03. The firm’s 50-day moving average price is $302.33 and its 200 day moving average price is $310.78.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.53. The firm had revenue of $907.00 million during the quarter, compared to analysts’ expectations of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. Illumina’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.52 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 6.44 EPS for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.